Positive mid-stage results for Regeneron's fasinumab

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has released positive top-line results from a placebo-controlled Phase II/III study evaluating fasinumab in patients with moderate-to-severe osteoarthritis pain of the hip or knee who have a history of inadequate pain relief or intolerance to current analgesic therapies.

At 16 weeks, patients treated with all four doses of fasinumab, an investigational nerve growth factor (NGF) antibody, demonstrated a statistically-significant improvement in pain relief, the primary endpoint of the study, as well as improvements in the secondary measure evaluating physical function.